ERBB2 and neoplasm: The addition of i14e vivo-MO targeting the 5SpS alone did not have inhibitory effects on tumor (Supplementary Fig. 7d); but notably, the combination of early treated T-DXd with i14e vivo-MO gave rise to more therapeutic effects on tumors than that with control vivo-MO in ERBB2 positive GBC cases (Fig. 5j, k and Supplementary Fig. 7e).